AMGN · Amgen Inc.

S&P 500 #61 · NASDAQ-100 #25 · Nasdaq

Risiko 4/10 · Large-Cap Biotech / Moderate · $393.10 ▲ 4.48%

Kennzahlen

• Price $393.10
• Market cap $212.2B
• P/E (ttm) 27.36
• Div yield 2.68%
• 52-wk range $269.77 – $398.00
• Index rank #61 / #25

Wichtigste Risiken

• Biosimilar competition on legacy drugs (Revenue) — MED
• Drug pricing / IRA policy pressure (Margins) — MED
• Obesity drug pipeline uncertainty (Growth outlook) — MED
• High R&D spend / clinical-trial risk (Earnings) — MED

Fazit

Amgen is rebounding on positive obesity-drug Phase 2 data and upward revenue guidance revisions, backed by a 2.8% yield — though biosimilar threats and IRA pricing reforms temper long-term upside.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.